Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Shares Crashed 32% Today

By Todd Campbell – Sep 2, 2016 at 4:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA has canceled a key advisory committee hearing to discuss Dynavax's hepatitis B vaccine.

Image source: Getty Images.

What happened

After the Food and Drug Administration announced earlier today that it had canceled an advisory committee meeting to evaluate its hepatitis B vaccine, shares in Dynavax Technologies Corp. (DVAX -2.09%) dropped 31.6% by market close.

So what

Dynavax Technologies' investors were dealt a blow in April when the FDA opted to delay an approval decision on Heplisav-B, the company's hepatitis B vaccine, and the FDA dealt another blow to the company today when it canceled the advisory committee meeting scheduled to consider the vaccine.

In August, Dynavax Technologies reported that the FDA's Vaccines and Related Biological Products committee would debate Heplisav-B's pros and cons on Nov. 16, yet only weeks later, the FDA has determined it needs more time "to review and resolve several outstanding issues."

The cancellation puts in jeopardy the FDA's ability to issue an approval decision on Heplisav-B's Dec. 15 PDUFA date.

Now what

The FDA did say that its evaluation is continuing and that it would schedule another advisory committee in the future, so this could simply be a delay and not an indication that the FDA has found something new and worrisome in the Heplisav-B data it's reviewing. The FDA previously rejected Heplisav-B, in 2013, because of worry that it could cause autoimmune disorders.

If Heplisav-B does eventually make it across the finish line to market, the opportunity could be big, because it offers an arguably better dosing schedule than GlaxoSmithKline's Engerix-B, the leading hepatitis B vaccine. Heplisav-B is given via two doses in one month, while Engerix-B is given via three doses over six months.

Nevertheless, Heplisav-B's past FDA setbacks make this company too risky for me to buy. Instead, I'm content to focus on other ideas that may be less risky.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$10.30 (-2.09%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.